echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > India's "development and Reform Commission" cut prices on essential drugs, Novartis refused!

    India's "development and Reform Commission" cut prices on essential drugs, Novartis refused!

    • Last Update: 2014-10-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: on October 15, 2014, Novartis confirmed to the outside world that the company had received a 30 billion rupee fine, but a company spokesman said that the company had raised doubts Novartis is working with NPPA )Play the real version of "price Guessing" (Note: "price Guessing" is an old American entertainment program The rules of the game are very simple As long as you guess the price of the product, the product is yours Since the program started, it has affected generations of Americans Many people want to get their favorite gifts through the program), because the company is selling well Novartis was not satisfied with the request of NPPA to reduce the price of the analgesic - Futalin, while NPPA believed that the authority was challenged and issued a fine of up to $49 million against Novartis In terms of drug pricing, disputes between pharmaceutical companies like Novartis and NPPA continue, and it is inevitable to go to court Novartis has confirmed to the outside world that it has received a 30 billion rupee ticket, but a company spokesman said, "before the high court in Delhi issued the ticket, we had already raised questions." According to media reports, India's NPPA lowered the price of 384 essential drugs in July 2013 and set a price ceiling Companies like GlaxoSmithKline, Sanofi and Novartis were among the most affected, as were companies like India's second-largest pharmaceutical company, sipura It is reported that NPPA only allows these enterprises 45 days to adjust or reduce their prices According to relevant data, Novartis' futaline is one of the top 10 best-selling drugs in India, but its growth rate has declined by 14.5% since last year To get rid of the pressure of litigation, NPPA set up a guideline this spring, saying it has the right to regulate the price of those drugs not listed in the national essential drug catalog In July this year, NPPA added more than 30 drugs to the national list of essential drugs, and set a maximum price for 110 drugs out of the list Some pharmaceutical companies once again take NPPA to court, but the impact of the price reduction order is immediate, especially in the capital market In Sanofi, for example, the company's share price fell 10% after the government's price reduction order Because the market is worried that NPPA will set a price ceiling on Sanofi's heart disease and diabetes drugs Some analysts predict that Sanofi's sales in India will fall by 9.5% and its profits will fall by 30% India's early election of prime minister last year, which launched Narendra moody, has shown that the government will take a more moderate approach to drug prices Last month, NPPA announced that it had lost the right to add to the national essential drug list Reuters reported that the government's right to restrict NPPA has no rules to follow, but the change has been seen as a sign of soft government by the organization of Indian drug manufacturers (oppi), which has filed a lawsuit in court against drug price reduction According to media reports, two Delhi high court judges recently informed pharmaceutical companies to hold tripartite talks with NPPA, and the government hopes to reach a consensus on this issue before the October 30 hearing, because the court is tired of drug price litigation    
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.